What’s the current market cap for Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals (ARWR) has a market cap of $11bn as of June 06, 2026.

What is the P/E ratio for Arrowhead Pharmaceuticals stock?

The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of June 06, 2026.

Does Arrowhead Pharmaceuticals stock pay dividends?

No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of June 06, 2026.

When is the next Arrowhead Pharmaceuticals dividend payment date?

Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.

What is the beta indicator for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (ARWR) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Arrowhead Pharmaceuticals stock | $ARWR Share Price

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

Ticker

$ARWR

Sector

Health

Primary listing

NASDAQ

Employees

711

Headquarters

Pasadena, United States

Website

arrowheadpharma.com

ARWR Metrics

BasicAdvanced

$11bn

-

-$2.17

1.29

-

What the Analysts think about ARWR

Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.

Bulls say / Bears say

Arrowhead posted Q1 FY2026 revenue of $264.0 million and net income of $30.8 million, a large increase from $2.5 million a year ago, signaling its transition to profitability as a commercial-stage business. (Business Wire)

Interim Phase 2 results showed that ARO-INHBE combined with tirzepatide led to 9.4% weight loss at 16 weeks versus 4.8% with tirzepatide alone, and ARO-ALK7 monotherapy achieved up to 94% mRNA knockdown, highlighting the potential for major new obesity drugs. (Business Wire)

Arrowhead raised $930 million via simultaneous offerings of 0% convertible senior notes and common stock, and ended Q1 with $916.6 million in cash and investments, ensuring enough funding for ongoing pipeline development without needing more dilutive capital soon. (Business Wire)

REDEMPLO® is aimed at familial chylomicronemia syndrome, which affects only about 6,500 people in the U.S., limiting the long-term revenue potential for Arrowhead’s first commercial product. (Business Wire)

Revenue in Q2 FY2026 fell to $73.7 million, down from $542.7 million in the same quarter last year, showing the company's earnings are unpredictable and heavily dependent on milestone payments rather than steady income. (Business Wire)

The new 0% convertible senior notes due 2032 have a conversion price of about $87 per share, introducing a risk of major equity dilution if holders decide to convert, which could put pressure on Arrowhead’s stock price. (Business Wire)

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

ARWR Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

ARWR Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

ARWR News

AllArticlesVideos

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

MarketBeat·11 hours ago

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Business Wire·4 days ago

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

MarketBeat·2 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Arrowhead Pharmaceuticals

Ticker

Employees

ARWR Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about ARWR

Analyst Ratings

Bulls say / Bears say

ARWR Financial Performance

Income Statement

ARWR Earnings Performance

Earnings per share (EPS)

ARWR News

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Buy $ARWR

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Arrowhead Pharmaceuticals/$ARWR

About Arrowhead Pharmaceuticals

Ticker

Employees

ARWR Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about ARWR

Analyst Ratings

Bulls say / Bears say

ARWR Financial Performance

Income Statement

ARWR Earnings Performance

Earnings per share (EPS)

ARWR News

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Buy $ARWR

Upcoming events

No upcoming events

What’s the current market cap for Arrowhead Pharmaceuticals stock?

What is the P/E ratio for Arrowhead Pharmaceuticals stock?

Does Arrowhead Pharmaceuticals stock pay dividends?

When is the next Arrowhead Pharmaceuticals dividend payment date?

What is the beta indicator for Arrowhead Pharmaceuticals?

Bulls say / Bears say